Removal of introns from messenger RNA precursors (pre-mRNA splicing) is an essential
step for the expression of most eukaryotic genes. Alternative splicing enables the regulated …

Polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF)
constitute theBCR-ABL1–negative myeloproliferative neoplasms and are characterized by …

Myelofibrosis: Clinicopathologic Features, Prognosis, and Management Page 1 Clinical
Advances in Hematology & Oncology Volume 16, Issue 2 February 2018 121 Myelofibrosis …

Myeloproliferative neoplasms (MPNs) are a group of clonal hematologic malignancies
morphologically characterized by expansion of terminally differentiated myeloid cells (white …

Although infectious complications represent a relevant cause of morbidity and mortality in
patients with myelofibrosis (MF), little is known about their incidence, outcome and risk …

Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are a group
of heterogeneous disorders of the hematopoietic system collectively known as Philadelphia …

Myelofibrosis (MF) is a clonal stem cell neoplasm characterized by abnormal JAK-STAT
signaling, chronic inflammation, cytopenias, and risk of transformation to acute leukemia …

The last decade has witnessed tremendous scientific advances, ushered in by the JAK2
V617F discovery, contributing to enhanced diagnostic capability and understanding of the …

The myeloproliferative neoplasms (MPNs) encompass a heterogenous set of diseases that
have variable survival, but in the setting of treatment refractory and progressive disease …

Hematopoietic cell transplantation (HCT) is the only curative therapeutic modality for
myelofibrosis (MF) at present. The optimal timing of HCT is not known in the presence of …